Defence Therapeutics (TSE:DTC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Defence Therapeutics has appointed Dr. Maxime Parisotto as its new Chief Scientific Officer and Director of Science and Business Development, aiming to leverage his extensive experience in drug development and oncology to enhance shareholder value. The company also granted Dr. Parisotto 100,000 incentive stock options, highlighting its commitment to driving growth through strategic leadership.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.